CJC-1295 (No DAC)

CJC-1295 No DAC (Modified GRF 1-29) is a 29-amino-acid synthetic analogue of GHRH incorporating four amino acid substitutions that confer DPP-4 resistance while preserving a short duration of activity — unlike DAC-modified long-acting analogues. This makes it relevant to research examining pulsatile growth hormone release patterns that follow physiological timing. FAB Research supplies CJC-1295 No DAC as a standalone 10mg research pen, separate from combination blends, for mechanistic investigation.

CJC-1295 No DAC binds at the GHRH receptor on pituitary somatotrophs, producing cAMP-mediated signalling and growth hormone release. The four substitutions confer DPP-4 resistance while retaining a half-life measured in minutes — so the compound supports pulsatile secretion patterns consistent with physiological growth hormone regulation. Research consistently documents synergistic release when combined with ghrelin receptor agonists acting through the separate GHS-R1a pathway.

A well-characterised literature built on decades of GHRH research, with specific study of the No DAC modification. GHRH receptor pharmacology characterised binding affinity and cAMP signalling. Stability research examined enzymatic resistance from the four substitutions. Pulsatility research compared secretion patterns with native GHRH and the long-acting DAC variant. Combination pharmacology documented well-established synergy with ghrelin receptor agonists. Note: listed by anti-doping authorities.

• 2.5 mg per application (one metered dose)
• 4 doses per pen (10 mg total)
• Modified GRF(1-29) without Drug Affinity Complex — short half-life (minutes); designed for pulsatile release study designs
• Pre-filled sterile solution — no reconstitution step required

Storage: Store refrigerated at 2–8 °C in the original sealed box. Do not freeze. Protect from light.

• For in-vitro laboratory and preclinical research only — not for human or animal administration
• No DAC form: half-life measured in minutes (DPP-4 resistant but no albumin-binding); appropriate for short-window, pulsatile GH release protocols
• DAC-modified CJC-1295 is a distinct compound with substantially longer half-life and different pharmacokinetics — confirm study design requirement specifies the no-DAC form
• Synergistic GH release when combined with GHS-R1a agonists (Ipamorelin, GHRP-2) through complementary receptor pathways

• Research data: headache, flushing — consistent with GHRH receptor agonism at the pituitary level
• Transient water retention
• Injection site reactions
• Short half-life limits duration of sustained-exposure effects compared with DAC-modified form
• No significant cortisol or prolactin elevation documented at studied doses

Effects listed are observations from published research literature and are not predictions for any specific use. All FAB Research products are for in-vitro laboratory research — not for human or animal administration.